

Notice of Postponement of “Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year”

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Shigeo Taniuchi; hereinafter, “Santen”) announced its board of directors approved a resolution today to postpone the transition to a holding company structure through sole-share transfer with effect from April 1, 2022, and the change of Santen’s fiscal year period starting Jan 1, 2022, which was previously resolved and announced on February 4, 2021.

1. Background

In order to solidly implement its long-term vision, Santen had prepared for the transition to a holding company structure and change of its fiscal year period, with the aim of establishing and enhancing a management and organizational system to enable swift and efficient execution, while dynamically managing businesses in transition as a result of ongoing geographic and business domain expansion.

However, Santen has made the decision to concentrate management resources on maximizing business value through the steady growth of its current business and the implementation of the next mid-term plan under the current corporate structure and fiscal year period. This is based on a comprehensive assessment of the short-term changes in the business environment in connection with the recording of an impairment loss mainly related to the development of STN2000100 (DE-128), as previously announced on April 9.

Regarding the implementation of this initiative, Santen will monitor the business environment as it considers the optimal timing on an ongoing basis. Santen will continue to further enhance the globalization of its business and organization as well as group governance.

2. Schedule

The schedule for transition to a holding company and change in fiscal year will be announced when decided.

3. Financial Impact

The financial impact on consolidated results for the year ending March 31, 2022 is negligible.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around

the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

Contact

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com